Vytorin Outcomes Comparison To Zocor Anticipated In 2008, Merck/Schering-Plough Say
Following delays in reporting data from ENHANCE, companies narrowed the study’s primary endpoint on the advice of an independent panel.
Following delays in reporting data from ENHANCE, companies narrowed the study’s primary endpoint on the advice of an independent panel.